These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
56. Natalizumab: risk stratification of individual patients with multiple sclerosis. Tur C; Montalban X CNS Drugs; 2014 Jul; 28(7):641-8. PubMed ID: 24942634 [TBL] [Abstract][Full Text] [Related]
57. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. Frohman EM; Monaco MC; Remington G; Ryschkewitsch C; Jensen PN; Johnson K; Perkins M; Liebner J; Greenberg B; Monson N; Frohman TC; Douek D; Major EO JAMA Neurol; 2014 May; 71(5):596-602. PubMed ID: 24664166 [TBL] [Abstract][Full Text] [Related]
58. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Cutter GR; Stüve O Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045 [TBL] [Abstract][Full Text] [Related]
59. Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod. Watanabe M; Nakamura Y; Isobe N; Tanaka M; Sakoda A; Hayashi F; Kawano Y; Yamasaki R; Matsushita T; Kira JI J Neuroinflammation; 2020 Jul; 17(1):206. PubMed ID: 32646493 [TBL] [Abstract][Full Text] [Related]
60. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Sørensen PS; Bertolotto A; Edan G; Giovannoni G; Gold R; Havrdova E; Kappos L; Kieseier BC; Montalban X; Olsson T Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]